Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis

  • Technology appraisal guidance
  • TA373
  • Published: 
Download guidance (PDF)

6 Recommendations for further research

6.1

The Committee noted a paucity of data on the effect of biological treatments for JIA on long‑term outcomes and quality of life. It noted that continued collection of data on long‑term outcomes and quality of life would improve the evidence base for juvenile idiopathic arthritis.